Company Profile (AI Text)
Name: EnGen Bio
Canonical URL: https://wefunder.com/engen.bio.llc
Updated at: 2026-06-02T05:00:40Z

Tagline: A Vaccine and Therapy to Provide Lifetime Protection from Flu Pandemics
Elevator pitch: EnGen Bio, LLC is a young biotech company focused on discovering and developing a universal influenza vaccine and therapy, and other unmet medical needs.

Key claims:
- Total raised on Wefunder: 1188482 | citation: https://wefunder.com/engen.bio.llc#claim-total-raised
- Total investors: 867 | citation: https://wefunder.com/engen.bio.llc#claim-total-investors

Verified facts:
- Total raised on Wefunder: 1188482 | observed_at: 2026-06-02T05:00:40Z | expires_at: 2026-06-03T05:00:40Z
- Total investors: 867 | observed_at: 2026-06-02T05:00:40Z | expires_at: 2026-06-03T05:00:40Z

Computed metrics:
- total_amount_raised: 1188482
- total_investors: 867
- team_size: 4
- featured_investor_count: 1
- faq_count: 5
- recent_post_count: 0

Quick facts:
- Potential for universal prevention of Type A flu and all flu pandemics in humans and animals. | citation: https://wefunder.com/engen.bio.llc#claim-fact-1
- Our vaccine could save 50K-250K lives a year and prevent untold suffering of millions caused by flu. | citation: https://wefunder.com/engen.bio.llc#claim-fact-2
- Veterinary applications to prevent all dog, horse, pig and bird flus. | citation: https://wefunder.com/engen.bio.llc#claim-fact-3
- Peak sales could reach 2.6B in the U.S. alone, in an $11.4B global market (not guaranteed). | citation: https://wefunder.com/engen.bio.llc#claim-fact-4
- 8 issued flu vaccine patents in major strategic markets. | citation: https://wefunder.com/engen.bio.llc#claim-fact-5
- Potential for early liquidity. | citation: https://wefunder.com/engen.bio.llc#claim-fact-6
- Experienced team of entrepreneurs with a combined total of 6 FDA approved drugs and >50 patents. | citation: https://wefunder.com/engen.bio.llc#claim-fact-7
- >50% of our lead investors are biotech execs and MDs who've vetted the science & its potential. | citation: https://wefunder.com/engen.bio.llc#claim-fact-8

FAQ:
- Q: Hi. What are your revenue goals for the next 5 years?
  A: Our goal is a many-fold return on your investment in the next 5 years. That would be as a result of at least one out-licensing event, most likely the flu vaccine, but possibly the flu antibody also. We are targeting a high sale price even though it would be a preclinical asset; but the disease market is large, the demand appears to be high for a universal influenza and universal pandemic influenza vaccine, and how we intend to structure the deal, we believe can justify a high value. While tha...
- Q: Which technology is the vaccine based on? Is it mRNA-based?
  A: We are focused on a site (aka an ‘epitope’) on a major protein of the influenza virus that when bound by an antibody can neutralize viral infectivity. The 'core' of the vaccine will necessarily be comprised of this epitope that we've discovered. More experimentation will determine which vaccine format delivers the best immunogenicity and neutralizing response for our epitope. A portion of this investment round is dedicated to this very topic, -optimizing immunogenicity of the epitope. Therefo...
- Q: I'm not asking for projections, just your personal revenue targets so I can have an idea of the company's growth potential.
  A: As mentioned before, it is essentially impossible to calculate with accuracy what revenues will be, and I am hesitant to provide numbers that might set inaccurate expectations. The exit numbers depend on the stage and quality of the licensing packages (esp the data, which is impossible to predict right now), and how seriously the buyer(s) want(s) the asset. I have been in-licensing and out-licensing pharmaceutical technologies and drug candidates for the duration of my career. There are indus...
- Q: Can you explain for investors and potential investors how initial financial distributions will go to your investors, BEFORE the founders see any returns? Investors could potentially be "made whole" on their investment in any initial distribution?
  A: The Company’s Operating Agreement provides for a 1X liquidation preference for all investors in the Company. Let me roughly outline the mechanics of distribution, (A version of this is answered in the FAQ sheet on the Ask A Question page. A full description is in the Operating Agreement). The first $5M of cash from an out-licensing event is retained by the Company. The goal of these funds is to develop additional out-licensing candidates, thereby creating an ongoing revenue stream. Any profit...
- Q: Your presentation is certainly compelling and the enthusiasm of your Lead Investor (both financially and what he said) is great. What I can't figure out is whether it is in the too good to be true category or a truly amazing investment opportunity. These will help: 1. First, m...
  A: Yes, tens of millions of dollars are required to bring a drug candidate through discovery, the clinic and to the market. New estimates seem to be about $500M-$1B. By the time a company has spent that much time, risk and money, the original investors are financially diluted to irrelevance. Hence our unique business model. License early for cash, and often. To that end, if we raise the $250K to break escrow, that should be sufficient to reach a critical milestone, or value inflection point. Tha...